Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Binkui Li

Showing results (51-60 of 88) with videos related to

Pageof 9
Sort By:
Nature Communications|September 10, 2024
Targeting PRMT3 impairs methylation and oligomerization of HSP60 to boost anti-tumor immunity by activating cGAS/STING signalingYunxing Shi, Zongfeng Wu, Shaoru Liu, et al.
International Journal of Surgery (London, England)|April 7, 2023
TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching studyYichuan Yuan, Wei He, Zhiwen Yang, et al.
Cancer Medicine|May 8, 2024
Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world studyLiang Qiao, Wei He, Guoying Wang, et al.
BMC Cancer|April 18, 2015
The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysisWei He, Qingli Zeng, Yun Zheng, et al.
Journal of Cancer Research and Clinical Oncology|May 26, 2020
Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching studyChenwei Wang, Yadi Liao, Jiliang Qiu, et al.
Annals of Translational Medicine|March 12, 2021
Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective studyZhiyu Qiu, Lujun Shen, Yiquan Jiang, et al.
Iscience|July 26, 2024
Monoacylglycerol acyltransferase-2 inhibits colorectal carcinogenesis in APC<sup>min+/-</sup> miceYanhong Lang, Chengrui Zhong, Lingling Guo, et al.
Alimentary Pharmacology & Therapeutics|August 1, 2018
Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysisWenwu Liu, Yun Zheng, Wei He, et al.
International Journal of Molecular Sciences|July 13, 2024
KLF4 Suppresses the Progression of Hepatocellular Carcinoma by Reducing Tumor ATP Synthesis through Targeting the Mir-206/RICTOR AxisYongjin Wang, Dinglan Zuo, Zhenkun Huang, et al.
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|August 28, 2023
Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular CarcinomaBinkui Li, Jiliang Qiu, Yun Zheng, et al.
Pageof 9

Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
Nature Communications|September 10, 2024
Targeting PRMT3 impairs methylation and oligomerization of HSP60 to boost anti-tumor immunity by activating cGAS/STING signalingYunxing Shi, Zongfeng Wu, Shaoru Liu, et al.
International Journal of Surgery (London, England)|April 7, 2023
TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching studyYichuan Yuan, Wei He, Zhiwen Yang, et al.
Cancer Medicine|May 8, 2024
Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world studyLiang Qiao, Wei He, Guoying Wang, et al.
BMC Cancer|April 18, 2015
The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysisWei He, Qingli Zeng, Yun Zheng, et al.
Journal of Cancer Research and Clinical Oncology|May 26, 2020
Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching studyChenwei Wang, Yadi Liao, Jiliang Qiu, et al.
Annals of Translational Medicine|March 12, 2021
Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective studyZhiyu Qiu, Lujun Shen, Yiquan Jiang, et al.
Iscience|July 26, 2024
Monoacylglycerol acyltransferase-2 inhibits colorectal carcinogenesis in APC<sup>min+/-</sup> miceYanhong Lang, Chengrui Zhong, Lingling Guo, et al.
Alimentary Pharmacology & Therapeutics|August 1, 2018
Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysisWenwu Liu, Yun Zheng, Wei He, et al.
International Journal of Molecular Sciences|July 13, 2024
KLF4 Suppresses the Progression of Hepatocellular Carcinoma by Reducing Tumor ATP Synthesis through Targeting the Mir-206/RICTOR AxisYongjin Wang, Dinglan Zuo, Zhenkun Huang, et al.
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|August 28, 2023
Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular CarcinomaBinkui Li, Jiliang Qiu, Yun Zheng, et al.
Pageof 9